Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood (2011) Vol. 118, Iss. 19, pp. 5227-5234
Open Access | Times Cited: 256

Showing 1-25 of 256 citing articles:

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 25, pp. 2379-2390
Open Access | Times Cited: 1851
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1861-1869
Closed Access | Times Cited: 717
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih, Omar Abdel‐Wahab, Jay P. Patel, et al.
Nature reviews. Cancer (2012) Vol. 12, Iss. 9, pp. 599-612
Closed Access | Times Cited: 650
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Ayalew Tefferi, Elisa Rumi, Guido Finazzi, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1874-1881
Open Access | Times Cited: 616
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics
Blood (2016) Vol. 129, Iss. 6, pp. 667-679
Open Access | Times Cited: 531
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
Ayalew Tefferi, Terra L. Lasho, Christy Finke, et al.
Leukemia (2014) Vol. 28, Iss. 7, pp. 1472-1477
Closed Access | Times Cited: 523
JAK/STAT signaling in hematological malignancies
William Vainchenker, Stefan N. Constantinescu
Oncogene (2012) Vol. 32, Iss. 21, pp. 2601-2613
Open Access | Times Cited: 477
The future of epigenetic therapy in solid tumours—lessons from the past
Nilofer S. Azad, Cynthia A. Zahnow, Charles M. Rudin, et al.
Nature Reviews Clinical Oncology (2013) Vol. 10, Iss. 5, pp. 256-266
Open Access | Times Cited: 321
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
Véronique Gelsi‐Boyer, Mandy Brecqueville, Raynier Devillier, et al.
Journal of Hematology & Oncology (2012) Vol. 5, Iss. 1
Open Access | Times Cited: 265
Comprehensive mutational profiling in advanced systemic mastocytosis
Juliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Blood (2013) Vol. 122, Iss. 14, pp. 2460-2466
Open Access | Times Cited: 244
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi, Terra L. Lasho, Thitina Jimma, et al.
Mayo Clinic Proceedings (2012) Vol. 87, Iss. 1, pp. 25-33
Open Access | Times Cited: 218
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Stefanie Göllner, Thomas Oellerich, Shuchi Agrawal‐Singh, et al.
Nature Medicine (2016) Vol. 23, Iss. 1, pp. 69-78
Open Access | Times Cited: 214
Polycomb repressive complex 2 is required for MLL-AF9 leukemia
Tobias Neff, Amit Sinha, Michael Kluk, et al.
Proceedings of the National Academy of Sciences (2012) Vol. 109, Iss. 13, pp. 5028-5033
Open Access | Times Cited: 213
Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer
Anne Laugesen, Jonas W. Højfeldt, Kristian Helin
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 9, pp. a026575-a026575
Open Access | Times Cited: 188
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Aaron T. Gerds, Jason Gotlib, Haris Ali, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 9, pp. 1033-1062
Open Access | Times Cited: 82
Driver mutations of cancer epigenomes
David M. Roy, Logan A. Walsh, Timothy A. Chan
Protein & Cell (2014) Vol. 5, Iss. 4, pp. 265-296
Open Access | Times Cited: 169
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi
Blood (2012) Vol. 119, Iss. 12, pp. 2721-2730
Open Access | Times Cited: 169
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Joannah Score, Claire Hidalgo-Curtis, Amy V. Jones, et al.
Blood (2011) Vol. 119, Iss. 5, pp. 1208-1213
Open Access | Times Cited: 166
EZH2 in normal and malignant hematopoiesis
Kirstin Lund, Peter D. Adams, Mhairi Copland
Leukemia (2013) Vol. 28, Iss. 1, pp. 44-49
Open Access | Times Cited: 163
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho, Thitina Jimma, Christy Finke, et al.
Blood (2012) Vol. 120, Iss. 20, pp. 4168-4171
Closed Access | Times Cited: 161
Epigenetics of hematopoiesis and hematological malignancies
Deqing Hu, Ali Shilatifard
Genes & Development (2016) Vol. 30, Iss. 18, pp. 2021-2041
Open Access | Times Cited: 148
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2016) Vol. 91, Iss. 12, pp. 1262-1271
Open Access | Times Cited: 148
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Zhimin Gu, Yuxuan Liu, Feng Cai, et al.
Cancer Discovery (2019) Vol. 9, Iss. 9, pp. 1228-1247
Open Access | Times Cited: 141
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
Shahper N. Khan, A. Jankowska, Reda Z. Mahfouz, et al.
Leukemia (2013) Vol. 27, Iss. 6, pp. 1301-1309
Closed Access | Times Cited: 124
A complex Polycomb issue: the two faces of EZH2 in cancer
Hanno Hock
Genes & Development (2012) Vol. 26, Iss. 8, pp. 751-755
Open Access | Times Cited: 124
Page 1 - Next Page

Scroll to top